Pediatric ADHD: 3 Recent Discoveries

According to the United States Census Bureau, approximately 7.5% of school-aged children in the United States have Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD).

1—FDA Approves New Medication
The FDA recently approved a new formulation of a stimulant designed to be taken before bed, in order to control early morning symptoms. The drug, FORNAY PM, is a new version of methylphenidate with DELEXIS, a proprietary drug delivery technology, to control the medication’s release.

“Many parents of children with ADHD note that the early morning routine is often one of the most chaotic times of day. The idea of dosing the medication the night before was our moon-shot solution to meeting this need,” says Dr. Randy Sallee, Chief Medical Officer at Ironshore Pharmaceuticals, which plans to make the drug available early next year. “The approval of JORNAY PM is a welcome treatment option for healthcare providers, patients and their caregivers that may affect the way physicians think about ADHD treatment going forward.”

2—Speaking of Methylphenidate…
Data published in BMC Psychiatry may indicated that the use of methylphenidate (MPH) for ADHD in boys may be associated with low body mass index (BMI). Analysis of data from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) database indicates an “association between MPH use in boys with ADHD and low BMI, although the effect was stronger in boys age 6 to 10 and with MPH use of less than 12 months,” states the article “Methylphenidate for ADHD Treatment May Be Associated With Low BMI,” by Emily Pond. Researchers concluded that the relationship is complex and that further research is needed.

3—Neurofeedback Training
New clinical trials are currently underway using a highly interactive model for coaching during neurofeedback for the treatment of ADHD. Neurofeedback is a method of retraining the brain, and this specific type of therapy utilizes a game-like activity on training screens. “During a training session, children play five or more training tasks, lasting five to nine minutes each. The trainer provides guidance to improve their rate, cheers them on during successful moments, and encourages them to keep trying when the reward rate slows down. The goal is to help children maintain a level of brain activity that is consistent with their age for 45 minutes while doing fairly boring training tasks,” according to the article “What Is Neurofeedback? A Game-Changing ADHD Treatment” by Vincent Monastra, PH.D. Dr. Monastra states that using this type of model, significant, sustained improvement has been consistently noted, and 50 to 75 percent of children treated for ADHD with neurofeedback show significant improvement.

Meridien Research has been conducting clinical research trials and studies since 2000 in central Florida.  All studies are administered by board certified doctors and highly-trained medical personnel in St. Petersburg, Tampa, Bradenton, Brooksville, Lakeland and Maitland.